GlaxoSmithKline (GSK) has released an update.
GlaxoSmithKline (GSK) has announced its plan to sell its remaining 4.2% stake in Haleon, which amounts to approximately 385 million shares. The sale will be executed through a placing to institutional investors, facilitated by an accelerated bookbuild offering process. This move comes after a series of share disposals by GSK, following the initial retention of a 12.94% stake in Haleon post-demerger.
For further insights into GSK stock, check out TipRanks’ Stock Analysis page.
